Download PDF
Thromb Haemost 1985; 53(01): 024-025
DOI: 10.1055/s-0038-1661229
Original Article
Schattauer GmbH Stuttgart

The Effect of Histamine (H2) Receptor Antagonists on the Fibrinolytic Activity In Vitro

Antoni Stadnicki
The Department of Gastroenterology, Silesian School of Medicine, Katowice, Poland
,
Teresa Kacperek
The Department of Gastroenterology, Silesian School of Medicine, Katowice, Poland
› Author Affiliations
Further Information

Publication History

Received 03 May 1984

Accepted 21 October 1984

Publication Date:
18 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

The effect of cimetidine and ranitidine on the fibrinolytic activity in vitro was tested. The inhibition rate of spontaneous lysis rose proportionally to the increasing drug doses. However, a similar effect was obtained with two other drugs of different chemical structures and pharmacological properties. Streptokinase activated fibrinolyse was not affected by either of the drugs at any concentration. Nor was clot formation affected in these experiment conditions.

The results of the tests in vitro indicate that inhibition of euglobulin fibrinolysis by H2-receptor antagonists is not specific for these drugs and not connected with their pharmacological properties. It is possible to assume that, during therapeutic use, cimetidine and ranitidine have no antifibrinolytic effect. Possible explanation and relevance of these observations are discussed.

Key words

Fibrinolytic activity - Clot structure - H2-receptor antagonist
 

  • References

  • 1 Konturek SJ, Obtulowicz W, Kwiecien N, Sito E, Mikoś E, Oleksy J. Comparison of ranitidine and cimetidine in the inhibition on histamine sham - feeding and meal induced gastric secretion in duodenal ulcer patients. Gut 1980; 12: 181-186
    PubMedGoogle Scholar
  • 2 Nowak A, Sadliński Cz, Górka Z, Nowakowska E, Rudzki J, Gibiński K. Ranitidine for treatment of acute gastro-intestinal haemorrhage. Hepatogastroenterol 1981; 28: 267-270
    PubMedGoogle Scholar
  • 3 Priebe JJ, Skillman JJ, Bushnell LS, Long PC, Silen W. Antacid versus cimetidine in preventing in acute gastrointestinal bleeding. N Engl Med 1980; 302: 426-430
    CrossrefPubMedGoogle Scholar
  • 4 Chakrabarti R, Thompson SG. Cimetidine and fibrinolysis. Lancet 1979; 2: 962
    PubMedGoogle Scholar
  • 5 Woodings EP, Dixon GT, Harrison C, Carey P, Richards DA. Ranitidine - a new H2-receptor antagonist. Gut 1981; 21: 187-191
    PubMedGoogle Scholar
  • 6 Kowalski E, Kopeć M, Niewiarowski S. An evaluation of the euglobulin method for the determination of fibrinolysis. J Clin Pathol 1959; 12: 215-218
    CrossrefPubMedGoogle Scholar
  • 7 Wolosowicz N, Niewiarowski S, Czerepko K. Method for determining epsilon-aminocaproic acid (EACA) in blood plasma, based on the antifibrinolytic properties of this compound. Thrombos Diathes Haemorrh 1963; 10: 309-316
    PubMedGoogle Scholar
  • 8 Hartert H. Blutgerinnungsstudien mit der Thromboelastographie, einem neuen Untersuchungsverfahren. Klin Wschr 1948; 26: 577-583
    CrossrefPubMedGoogle Scholar
  • 9 Gryglewski RJ. The fibrinolytic activity of anti-inflammatory drugs. J. Pharm Pharmacol 1966; 18: 474
    CrossrefPubMedGoogle Scholar
  • 10 Baillie AJ, Sim AK. The effects of some synthetic compounds on in vitro fibrinolytic activity measured by different methods and the relevance to activity in vivo. Thrombos Diathes Haemorrh 1972; 28: 351-358
    PubMedGoogle Scholar
  • 11 Lübcke P, Hermann W. Auswirkungen von Cimetidine und Ranitidine auf die plasmatische Gerinnungsfähigkeit des Blutes. Dtsch Med Wschr 1982; 107: 1671-1674
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Lübcke P, Eyme B. Histamin H-2-Rezeptor-Antagonisten bei akuten intestinalen Blutungen. Intensivmed 1983; 20: 117-120
    PubMedGoogle Scholar